Exciting results obtained by our decision-support platform - we presented our research at #AACR2018 and showed other cancer researchers our discovery of how CureMatch is revolutionizing Cancer treatment today. This study highlights the possible benefits of an evidence-based selection of personalized therapy options in terms of patient response, and validates the data mining methods and optimized algorithms used by the CureMatch PreciGENE® therapeutic decision-support system.
Next-generation sequencing study validates a core principle behind the CureMatch technology SAN DIEGO, CA – February 16, 2017 – CureMatch, the developer of a decision support platform for combination therapy in cancer, today announced that research from their co-founder and Chief Medical Advisor, Dr. Razelle Kurzrock, was selected by the American Society of Clinical Oncology […]
A multi-year study was performed by UCSD oncologist and CureMatch co-founder Dr. Razelle Kurzrock and colleagues, and looked at 291 patients with advanced cancers, who had received either the standard of care (n = 116) or personalized cancer therapy (n = 175). Patients treated using the standard of care, which was based on their type of cancer, had […]
A study was performed of more than 300 patients with diverse refractory cancers, including ovarian cancer, breast cancer, sarcoma, and renal cancer who had undergone next-generation sequencing of their tumor. “Matching Scores” were calculated for each patient based on the number of drug matches and genomic aberrations. It was found that high Matching Scores were […]
An observational study of 180 patients with solid advanced cancers found that matching patients with drugs targeting their genomic anomalies was associated with better outcomes. Further, when a “Matching Score” that integrated the number of matches and number of alterations was used, the Matching Score was predictive of longer survival. The study also suggested that […]
